| Product Code: ETC13369849 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Vaccine Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Vaccine Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Vaccine Market Revenues & Volume, 2021 & 2031F |
3.3 North America Vaccine Market - Industry Life Cycle |
3.4 North America Vaccine Market - Porter's Five Forces |
3.5 North America Vaccine Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Vaccine Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 North America Vaccine Market Revenues & Volume Share, By Disease Indication, 2021 & 2031F |
3.8 North America Vaccine Market Revenues & Volume Share, By Age Group, 2021 & 2031F |
3.9 North America Vaccine Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 North America Vaccine Market Revenues & Volume Share, By Technology, 2021 & 2031F |
4 North America Vaccine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Vaccine Market Trends |
6 North America Vaccine Market, 2021 - 2031 |
6.1 North America Vaccine Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Vaccine Market, Revenues & Volume, By Preventive Vaccines, 2021 - 2031 |
6.1.3 North America Vaccine Market, Revenues & Volume, By Therapeutic Vaccines, 2021 - 2031 |
6.1.4 North America Vaccine Market, Revenues & Volume, By DNA Vaccines, 2021 - 2031 |
6.2 North America Vaccine Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Vaccine Market, Revenues & Volume, By Influenza, 2021 - 2031 |
6.2.3 North America Vaccine Market, Revenues & Volume, By COVID19, 2021 - 2031 |
6.2.4 North America Vaccine Market, Revenues & Volume, By Hepatitis B, 2021 - 2031 |
6.3 North America Vaccine Market, Revenues & Volume, By Age Group, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Vaccine Market, Revenues & Volume, By Pediatrics, 2021 - 2031 |
6.3.3 North America Vaccine Market, Revenues & Volume, By Adults, 2021 - 2031 |
6.3.4 North America Vaccine Market, Revenues & Volume, By Geriatrics, 2021 - 2031 |
6.4 North America Vaccine Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.4.2 North America Vaccine Market, Revenues & Volume, By Intramuscular, 2021 - 2031 |
6.4.3 North America Vaccine Market, Revenues & Volume, By Subcutaneous, 2021 - 2031 |
6.4.4 North America Vaccine Market, Revenues & Volume, By Oral, 2020 - 2028 |
6.5 North America Vaccine Market, Revenues & Volume, By Technology, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 North America Vaccine Market, Revenues & Volume, By mRNAbased, 2020 - 2028 |
6.5.3 North America Vaccine Market, Revenues & Volume, By Viral Vector, 2020 - 2028 |
6.5.4 North America Vaccine Market, Revenues & Volume, By Protein Subunit, 2020 - 2028 |
7 North America Vaccine Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Vaccine Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.1 United States (US) Vaccine Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.2 Canada Vaccine Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.3 Rest of North America Vaccine Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3 North America Vaccine Market Revenues & Volume Share, By Disease Indication, 2021 & 2031F |
7.3.1 United States (US) Vaccine Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.3.2 Canada Vaccine Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.3.3 Rest of North America Vaccine Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4 North America Vaccine Market, Revenues & Volume, By Age Group, 2021 - 2031 |
7.4.1 United States (US) Vaccine Market, Revenues & Volume, By Age Group, 2021 - 2031 |
7.4.2 Canada Vaccine Market, Revenues & Volume, By Age Group, 2021 - 2031 |
7.4.3 Rest of North America Vaccine Market, Revenues & Volume, By Age Group, 2021 - 2031 |
7.5 North America Vaccine Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.1 United States (US) Vaccine Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.2 Canada Vaccine Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.3 Rest of North America Vaccine Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Vaccine Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.6.1 United States (US) Vaccine Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.6.2 Canada Vaccine Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.6.3 Rest of North America Vaccine Market, Revenues & Volume, By Technology, 2021 - 2031 |
8 North America Vaccine Market Key Performance Indicators |
9 North America Vaccine Market - Export/Import By Countries Assessment |
10 North America Vaccine Market - Opportunity Assessment |
10.1 North America Vaccine Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Vaccine Market Opportunity Assessment, By Type, 2021 & 2031F |
10.3 North America Vaccine Market Opportunity Assessment, By Disease Indication, 2021 & 2031F |
10.4 North America Vaccine Market Opportunity Assessment, By Age Group, 2021 & 2031F |
10.5 North America Vaccine Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10.6 North America Vaccine Market Opportunity Assessment, By Technology, 2021 & 2031F |
11 North America Vaccine Market - Competitive Landscape |
11.1 North America Vaccine Market Revenue Share, By Companies, 2022 |
11.2 North America Vaccine Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here